Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026119 | 0.92 | LMNA (0.55) | LMNASLC22A6TSHRTHRBBLM | |
| SCHEMBL11097531 | 0.90 | TSHR (0.57) | LMNASLC22A6TSHRTHRBBLM | |
| SCHEMBL7606907 | 0.90 | TSHR (0.57) | LMNASLC22A6TSHRTHRBBLM | |
| SCHEMBL1463490 | 0.83 | — | — | |
| SCHEMBL21110663 | 0.82 | CA1 (0.37) | LMNASLC22A6TSHRTHRBBLM | |
| SCHEMBL3169639 | 0.81 | ARG1 (0.32) | LMNATSHRBLMKMT2AAPEX1 | |
| Succinic Acid SCHEMBL29243143 | 0.78 | GPR84 (0.56) | LMNASLC22A6TSHRBLMKMT2A | |
| Succinic Acid SCHEMBL29243141 | 0.78 | GPR84 (0.56) | LMNASLC22A6TSHRBLMKMT2A | |
| SCHEMBL11330927 | 0.78 | APEX1 (0.68) | LMNASLC22A6TSHRTHRBBLM | |
| SCHEMBL12666039 | 0.77 | ARG1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285446-A | Synthesis method of 4-sulfamoyl butyric acid | 成都普康生物科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-107200905-B | A kind of micro-elasticity plastics sheep bed and its preparation method and application | 山东阳春羊奶乳业有限公司 | 2019-08-13 | — | — | CN | claimed |
| CN-108703954-A | A kind of preparation method of Ezetimibe piece | 广州维奥康药业科技有限公司 | 2018-10-26 | — | — | CN | claimed |
| CN-105254687-B | A kind of synthetic method of amikacin | 齐鲁天和惠世制药有限公司 | 2018-06-19 | — | — | CN | claimed |
| CN-107200905-A | A kind of micro-elasticity plastics sheep bed and its preparation method and application | 山东阳春羊奶乳业有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-102216279-A | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO LTD | 2011-10-12 | — | — | CN | claimed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | claimed |
| US-7166696-B2 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-23 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040265899-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | claimed |
| US-6787635-B2 | azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-07 | — | — | US | claimed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | claimed |
| EP-1373167-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M Innovative Properties Company (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003068806-A1 | SOLID PHASE PEPTIDE SYNTHESIS ON SILICA | JOHNSON MATTHEY PLC (GB) | 2003-08-21 | — | — | WO | claimed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | claimed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002081078-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
| EP-4731269-A1 | RADIOLABELED COMPOUND FOR USE IN A METHOD OF TREATING CARBONIC ANHYDRASE IX POSITIVE DISEASES | Debiopharm International SA (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-5192774-A | SUBSTITUTED ACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIULCER DRUG CONTAINING SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0404949-A1 | SUBSTITUTED ACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIULCER DRUG CONTAINING SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173051-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | LMNA 1506/4885SLC22A6 2246/4885TSHR 3025/4885 |
| US-20040265899-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | LMNA 1506/4885SLC22A6 2246/4885TSHR 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.